Literature DB >> 26370515

REVascularization with paclitaxEL-coated balloon angioplasty versus drug-eluting stenting in acute myocardial infarcTION-A randomized controlled trial: Rationale and design of the REVELATION trial.

Nicola S Vos1, Rene J van der Schaaf1, Giovanni Amoroso1, Jean-Paul R Herrman1, Mark S Patterson1, Ton Slagboom1, Maarten A Vink1.   

Abstract

AIM: In primary percutaneous coronary intervention (PPCI) for ST-elevation myocardial infarction (STEMI), stenting has proved to reduce the need for repeat revascularization compared with balloon angioplasty alone. The incidence of cardiac death or recurrent myocardial infarction, though, is not reduced by stenting. This is in part attributable to stent-related complications like stent thrombosis which may occur even years after implantation. A strategy of drug coated balloon (DCB) angioplasty without stenting would abolish the potential disadvantages of stent implantation while reducing the probability of restenosis observed in plain old balloon angioplasty. Our aim is to evaluate the efficacy and safety of a DCB only strategy versus drug-eluting stents (DES) in PPCI for STEMI. STUDY
DESIGN: The REVELATION trial is a prospective, single center, randomized study, in which 120 patients presenting with STEMI will be allocated to treatment with a DCB versus DES. Appertaining to the established prognostic value of fractional flow reserve (FFR) rather than angiographic lesion severity, the functional assessment of the infarct-related lesion by FFR at 9 months after initial treatment is the primary end point. Assuming an FFR value of 0.90 after stenting and an increased risk of adverse events if post-PCI FFR <0.85, we decided to accept an FFR value of ≥0.85 after DCB only at follow-up as noninferiority margin. Secondary end points include major adverse cardiac events up to 5-year follow-up.
CONCLUSION: Our trial will address the efficacy and safety of DCB angioplasty versus DES in the setting of PPCI for STEMI. The REVELATION trial will introduce the recognized prognostic significance of physiologic assessment of the infarct-related lesion by FFR at 9 months follow-up as primary end point.
© 2015 Wiley Periodicals, Inc. © 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  ST-segment elevation myocardial infarction; drug-coated balloon; fractional flow reserve; primary percutaneous coronary intervention

Mesh:

Substances:

Year:  2015        PMID: 26370515     DOI: 10.1002/ccd.26241

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  4 in total

Review 1.  Application of drug-coated balloon in coronary artery intervention: challenges and opportunities.

Authors:  Lei Gao; Yun-Dai Chen
Journal:  J Geriatr Cardiol       Date:  2016-11       Impact factor: 3.327

2.  CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) in 2018.

Authors:  Yukio Ozaki; Yuki Katagiri; Yoshinobu Onuma; Tetsuya Amano; Takashi Muramatsu; Ken Kozuma; Satoru Otsuji; Takafumi Ueno; Nobuo Shiode; Kazuya Kawai; Nobuhiro Tanaka; Kinzo Ueda; Takashi Akasaka; Keiichi Igarashi Hanaoka; Shiro Uemura; Hirotaka Oda; Yoshiaki Katahira; Kazushige Kadota; Eisho Kyo; Katsuhiko Sato; Tadaya Sato; Junya Shite; Koichi Nakao; Masami Nishino; Yutaka Hikichi; Junko Honye; Tetsuo Matsubara; Sumio Mizuno; Toshiya Muramatsu; Taku Inohara; Shun Kohsaka; Ichiro Michishita; Hiroyoshi Yokoi; Patrick W Serruys; Yuji Ikari; Masato Nakamura
Journal:  Cardiovasc Interv Ther       Date:  2018-03-29

3.  Analysis of the clinical value of fractional flow reserve for prognosis evaluation of patients of percutaneous coronary intervention.

Authors:  Qingxia Zhao; Zheng Ji; Xia Li; Yali Di; Haojun An; Bin Wei; Liming Yang; Wensheng Chen
Journal:  Exp Ther Med       Date:  2017-11-01       Impact factor: 2.447

Review 4.  Drug-Coated Balloon-Only Percutaneous Coronary Intervention for the Treatment of De Novo Coronary Artery Disease: A Systematic Review.

Authors:  Hasan Mohiaddin; Tamar D F K Wong; Anne Burke-Gaffney; Richard G Bogle
Journal:  Cardiol Ther       Date:  2018-10-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.